BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 19903491)

  • 21. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery.
    Eidelman O; Zhang J; Srivastava M; Pollard HB
    Am J Pharmacogenomics; 2001; 1(3):223-38. PubMed ID: 12083969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
    Perrem L; Ratjen F
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
    Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB
    Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis.
    Elborn JS
    Lancet; 2016 Nov; 388(10059):2519-2531. PubMed ID: 27140670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of CFTR in airway disease.
    Pilewski JM; Frizzell RA
    Physiol Rev; 1999 Jan; 79(1 Suppl):S215-55. PubMed ID: 9922383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.
    Kwilas AR; Yednak MA; Zhang L; Liesman R; Collins PL; Pickles RJ; Peeples ME
    J Virol; 2010 Aug; 84(15):7770-81. PubMed ID: 20504917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis.
    Reihill JA; Douglas LEJ; Martin SL
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33810137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.
    Barry PJ; Ronan N; Plant BJ
    Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells.
    Kumar P; Bhattacharyya S; Peters KW; Glover ML; Sen A; Cox RT; Kundu S; Caohuy H; Frizzell RA; Pollard HB; Biswas R
    Gene Ther; 2015 Nov; 22(11):908-16. PubMed ID: 26133785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene therapy in cystic fibrosis.
    Prickett M; Jain M
    Transl Res; 2013 Apr; 161(4):255-64. PubMed ID: 23273902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.
    Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M
    Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapies in cystic fibrosis.
    Ratjen F; Grasemann H
    Curr Pharm Des; 2012; 18(5):614-27. PubMed ID: 22229570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients.
    Amaral MD
    J Intern Med; 2015 Feb; 277(2):155-166. PubMed ID: 25266997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.